Neoscience Sdn Bhd’s Post

The proto-oncogene HER-2/neu (C-erbB-2) has been localized to chromosome 17q and encodes a transmembrane tyrosine kinase growth factor receptor. The name for the HER-2 protein is derived from “Human Epidermal growth factor Receptor,” as it features substantial homology with the epidermal growth factor receptor (EGFR). HER-2/neu gene amplification has been associated with the development of breast cancer in animal models. The HER-2/neu protein is a component of a four-member family of closely related growth factor receptors, including EGFR or HER-1 (erb-B1); HER-2 (erb-B2); HER-3 (erb-B3) and HER-4 (erb-B4).

Some rare central nervous system tumors—including a new subtype of ependymoma and some medulloblastomas—contain changes in genes called MYC and MYCN. Tumors with these genetic alterations were once considered “undruggable.” However, in a new NCI-supported clinical trial, a chemotherapy drug called PLX038 will be tested to try to control or prevent the growth of cancer cells in tumors with these gene changes. Learn more: https://go.nih.gov/dHc9mCw Media Description: Microscopy images of four different MYCN amplified ependymomas. The bright spots indicate extra copies of the MYCN gene. Media Credit: Raffeld et al. Acta Neuropathologica Communications. 2020 Dec; 8(1):1-1.

#transcript Dr. Mollie Leoni, Executive Vice President for Clinical Development of Kura Oncology discusses the company's ziftomenib program, a menin inhibitor for acute myeloid leukemia (AML). The company found that specific subtypes, such as those with NPM1 mutation or KMT2A rearrangement, were more likely to respond to the menin inhibitor. Understanding the role of menin and menin inhibitors in addressing abnormal gene expression and promoting healthy cell development opens the door to potential combination therapy, where menin inhibitors could be layered onto existing treatments for various cancers related to menin independence. #MeninInhibitors #PrecisionMedicine #BTD KuraOncology.com https://lnkd.in/g-cxq8fN

Very recently, ovarian clear cell carcinoma patients with inactivating mutations in PPP2R1A, a gene coding for a scaffold component of PP2A, and treated with immune checkpoint inhibitors (ICI), were found have markedly longer survival than patients without the mutation in their cancers. Retrospective reviews of patients with a variety of cancers treated with ICI or chemotherapy show much longer survival of ICI-treated patients with a PPP2R1A mutation in their tumors. Given these preclinical and clinical observations, it is likely that LB-100 may be a general way to enhance ICI responses. Learn more at lixte.com. #LB100 #LIXTE #oncology #PP2A #inhibitors #cancertherapy

Researchers have made a pivotal breakthrough in clinical trials, especially for those battling pancreatic cancer. A study reveals the brand of basement membrane extract (BME) used in cultivating patient-derived organoids (PDOs) does not impact drug response or gene expression.   This allows flexibility in BME selection for researchers, speeding up organoid growth and enabling faster, personalized treatment approaches. Especially significant for pancreatic cancer research, this could mean faster treatment adaptation for patients, offering a glimmer of hope against one of the most aggressive cancers. #PancreaticCancerResearch #ClinicalTrials https://lnkd.in/eazVx7Cu

ASCO #GU24 –A study sought to evaluate the real-world effectiveness of poly ADP-ribose polymerase (PARP) inhibitors in patients with homologous recombination repair gene alterations and explore the clinical validity of Foundation Medicine’s homologous recombination deficiency signature (HRDsig) biomarker to additionally predict outcomes on PARPi in patients with metastatic castration resistant prostate cancer. Full abstract at the link here: https://bit.ly/47JhhDC

New! Repositioning of #antiarrhythmics for #prostatecancer treatment: a novel strategy to reprogram #cancerassociatedfibroblasts towards a tumor-suppressive phenotype ---------------- Cancer-associated fibroblasts (CAFs) play a significant role in fueling prostate cancer (PCa) progression by interacting with tumor cells. A previous gene expression analysis revealed that CAFs up-regulate genes coding for voltage-gated cation channels, as compared to normal prostate fibroblasts (NPFs). In this study, Zaffaroni Nadia, Valentina Doldi, Paolo Gandellini et al. explored the impact of antiarrhythmic drugs, known cation channel inhibitors, on the activated state of CAFs and their interaction with PCa cells. Look here👇 https://lnkd.in/dXa_Y5Yk #DrugRepositioning #Tumormicroenvironment IFO - Istituto Nazionale Tumori Regina Elena - Istituto Dermatologico San Gallicano

This week Aanastra Inc and DIVINCELL will be at the Advancing Gene and Cell Therapies for Cancer Conference (American Society of Gene & Cell Therapy), taking place October 16-17, 2024, in Philadelphia,. https://lnkd.in/eswMGcxg We will present our RNA-based therapeutic platform to target aberrant genetic disorders and oncogenes in cancer  ▶ "mRNA-mediated Rescue of Lost Tumor Suppressor Function in Mutated p53 or BRCA1 Tumors is a Potent New Strategy for Cancer Therapy Delivered with Tumor-Targeted Peptide (non-LNP) Nanoparticles ". Abstract 24. ▶ "In Vivo CRISPR Gene Editing of KRAS Mutant Tumors with Tumor-Targeted (non-LNP) Peptide-based Nanoparticles Causes Strong Tumor Regressions with Only 2 Doses and Overcomes Resistance to Existing Small-Molecule KRAS Inhibitors". Abstract 25. #p53 #KRAS #CRISPR #BRCA-1 #BRCAness #nanotechnology #drugdelivery #mRNA #ASGCTAdvancing24 #ASGCT #geneediting

$GNPX should be on your radar! Genprex, Inc. (NASDAQ: GNPX) is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Advancing novel gene therapies for patients afflicted with cancer or diabetes. Our lead drug candidate, REQORSA® Immunogene Therapy (quaratusugene ozeplasmid) for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), is designed to interrupt cell signaling pathways that cause replication and proliferation of cancer cells, target and kill cancer cells, and stimulate the natural immune responses against cancer. https://lnkd.in/g9QEMbTa

At Simsen Diagnostics we collaborate with a diverse range of experts in the field, including with physicians in clinical practice. One such collaborator is Dr. Martin Dalin, a pediatrician from Sahlgrenska University Hospital, who has been using SiMSen-Seq—our core technology—in his research for several years.    Recently, he and his research group published a paper demonstrating the clinical potential of a targeted ALK panel for ctDNA analysis in patients with ALK-mutated neuroblastoma treated with the ALK inhibitor lorlatinib.   Note: This refers to a group of patients who have a specific type of cancer, neuroblastoma, that has mutations in the ALK gene. Neuroblastoma is a type of cancer that mostly affects children, and ALK mutations can drive its growth.  Lorlatinib is a drug that specifically targets and inhibits the activity of the mutated ALK gene.   Read the whole paper below (in the comments)